Virpax Pharmaceuticals Inc - VRPX STOCK NEWS

Virpax Pharmaceuticals (NASDAQ:VRPX) has engaged Torreya Capital, LLC as its exclusive financial advisor for global licensing and partnership efforts. Torreya has a strong track record in the life sciences sector, facilitating over $100 billion in transactions since 2007. CEO Anthony Mack emphasized the rising demand for non-opioid pain relief, citing their product candidates: Epoladerm™, Probudur™, and Envelta™. Torreya aims to locate strong regional partners to enhance Virpax's innovative pipeline focused on non-addictive pain management solutions.

Virpax Pharmaceuticals (NASDAQ:VRPX) announced promising results from an animal study on MMS019, its anti-viral candidate for respiratory viruses. Led by Professor Krzysztof Pyrc, the study showed that MMS019 inhibited viral replication in the nasal passages of treated mice. Additionally, reduced virus levels were noted in brain tissue, which may have implications for neurological impacts of severe COVID-19. The Company is collaborating with Syneos Health to navigate regulatory pathways for an NDA submission to the FDA.

Virpax Pharmaceuticals (NASDAQ:VRPX) announced positive results from a preclinical study on its liposomal bupivacaine product, Probudur™. The study assessed neurotoxicity in rabbits, revealing no motor or sensory nerve damage at doses 10 times higher than free bupivacaine. While free bupivacaine showed mild neurotoxicity, Probudur™ demonstrated a favorable safety profile, with only mild inflammation noted. This promising data will support their FDA Investigational New Drug Application (IND) submission. Virpax focuses on developing non-addictive pain management therapies.

Virpax Pharmaceuticals (NASDAQ:VRPX) announced the initiation of preclinical studies for Probudur, a long-acting injectable local anesthetic utilizing liposomal technology. Conducted in partnership with Charles River Laboratories, the studies include seven animal trials focused on dosage and toxicity as part of the FDA's Investigational New Drug Application requirements. The FDA has suggested pursuing a 505(b)(2) NDA for Probudur, with the potential to advance to Phase 2A clinical trials upon completion. Early animal studies indicate Probudur may offer significantly extended analgesic activity compared to existing products.

Virpax Pharmaceuticals (NASDAQ: VRPX) has partnered with Charles River Laboratories to commence preclinical studies for Epoladerm™, a patented topical spray for acute musculoskeletal pain. This agreement includes seven animal studies to ascertain the necessary dosages and toxicity for FDA compliance. Following these studies, Virpax plans to submit its Investigational New Drug Application in H1 2021. Epoladerm™ uses a meter-dosed film to deliver Diclofenac Epolamine and is expected to accelerate the drug approval process.

Virpax Pharmaceuticals (NASDAQ:VRPX) announced the issuance of US Patent No. 10842745 for a liposomal composition containing bupivacaine, set to expire in 2029. This patent, exclusively licensed to Virpax from LipoCure Rx, includes 18 claims related to methods for providing analgesia. CEO Anthony Mack expressed satisfaction with the growing patent portfolio for Probudur™, a long-acting anesthetic for postoperative pain management. The company is focused on developing non-addictive pain management products using proprietary technologies.

Nanomerics Ltd announced receiving its first milestone payments from Virpax Pharmaceuticals (NASDAQ:VRPX). These payments are linked to the licensing of Envelta™ for non-cancer pain treatment and MMS019, an antiviral nasal spray. Virpax is responsible for clinical development under agreements with the U.S. National Center for Advancing Translational Sciences. This collaboration supports the development of innovative treatments amid the opioid crisis and viral infections, potentially enhancing both companies’ market positions.

Virpax Pharmaceuticals (NASDAQ:VRPX) announced the initiation of IND enabling studies for its intranasal enkephalin drug candidate, Envelta™, in collaboration with the National Center for Advancing Translational Sciences (NCATS). This partnership aims to expedite the company's path towards FDA clearance for its first-in-human clinical trials. Envelta™ utilizes nanotechnology for drug delivery directly to the brain, potentially offering a non-addictive pain management alternative. The CEO emphasized that these studies mark significant progress in clinical development strategy.

Virpax Pharmaceuticals has successfully closed its IPO, offering 1,800,000 shares at $10.00 each, raising $18.0 million before expenses. The underwriters received a 30-day option to purchase an additional 270,000 shares for over-allotments. The net proceeds will primarily fund research for its product pipeline, including Epoladerm™ and Probudur™, among others. The registration statement was filed with the SEC and became effective on February 16, 2021.